Although most American patients need to undergo surgery at the same time as the local hospital’s requirements.

However, there were also many patients in the first batch of surgery. In the first week of the launch of the United States, 100,000 doses were sold, which means that more than 50,000 American patients have used this advanced cardiac therapy agent.

Soon, these first batch of patients who received treatment shared their entire treatment experience in various patient social circles.

It was nothing more than a small interventional surgery on the first day, and after two injections of medicine, he recovered in bed for three days. The heart's self-discipline problem was easily solved, and the regular and powerful beating was restored!

In particular, some patients even took some videos of running on the treadmill like a show-off and posted them in the group, which aroused the excitement of many patients who were queuing up to receive treatment.

Many patients even stuffed money to the hospital after seeing the effect so well and asked for an expedited operation.

You don’t make a bastard if you have money!

Among all hospitals in the United States, whether public or private, as long as they have a cardiology department and can undergo interventional surgery, they immediately fall into a busy period. Even the attendees who don’t like to work overtime, under the temptation of huge rewards, have also taken the initiative to apply for overtime.

On average, one hospital can perform interventional injection surgery with eight to ten myocardial healing agents a day!

Many patients who have implanted their pacemakers are far from their lifespan have abandoned pacemakers that can continue to work for several years and choose to receive treatment for cardiomyocyte healing agents. They don’t want to wear pacemakers more for a day!

There are a total of millions of patients with pacemaker implanted in the United States, and nearly half of them have the intention to remove pacemakers. To meet the surgical needs of these patients, thousands of American hospitals will take a year and a half to perform surgery on their patients.

Cardiologists in the United States also began to feel the pain and happiness of Chinese cardiologists last year, and the happiness of cardiologists in the United States was doubled because they received much more money than cardiologists in China...

However, all of this has nothing to do with Chen Changan, and he has not even paid much attention to the subsequent development of cardiomyocyte healing agents in the United States.

At present, the global shipment of this drug has reached the level of tens of millions of units. Basically, all countries are introducing and using this drug. Although the American market is very important and the patients' economic capabilities are the best in the world, since the dust has been settled and will be steadily sold in the future, there is no need for Chen Changan to pay attention.

What he is more concerned about now is the situation after cancer gene editing drugs are put into use in Denmark!

This is the focus of Ruikang Medical’s next work!

You should know that the number of new cancer cases worldwide exceeds 20 million every year! The number of cancer deaths each year also exceeds 9 million!

In other words, more than 20 million people will be diagnosed with new cancer every year, and more than 9 million people will die of cancer!

And this proportion is still rising year by year!

According to statistics from the World Health Organization, globally, the probability of men suffering from cancer in their lifetime is 1/3, while that of women is 1/4. What a terrible number!

Although many cancers will not die quickly, the number of cancer survivors has been growing. In China alone, there are more than 10 million cancer survivors, and many cancer patients have been clinically cured or survived with tumors, but the impact of cancer on human society is still growing rapidly.

If Ruikang Medical's cancer gene editing drug can be launched globally, even if it can only be effective for more than 30 common cancers and cancers with high mortality rates, it can also contribute greatly to human medical care.

And you can also make a lot of money.

But when Chen Changan thought of this, it was a pity.

In the Ruikang headquarters in Binhai Building, Gusu City, Chen Changan said to Guan Kou with a tangled look on his face: "So, our cancer gene editing drugs are currently ineffective against it?"

"Yes, Mr. Chen and Professor Yunheng have made a lot of attempts, but have not made good progress. Since nmsc is a skin cancer, our gene editing drugs cannot accurately and effectively trigger the immune mechanism on skin tissues, so they are temporarily helpless against this skin cancer."

nmsc, which is non-melanoma skin cancer, is the most common cancer in the world. Among the more than 20 million new cancer patients each year, more than 7 million are nmsc patients.

However, the mortality rate of this type of cancer is not high. Only tens of thousands of patients die from this type of cancer every year. Most patients can basically recover from their health after removing the cancerous cell tissue. Even if they recur twice in three to five years, they can continue to be removed.

Only some patients who have reached the late stage and whose skin is infected with this skin cancer on their body cannot be treated.

Although the malignancy of this cancer is not very high and the patient mortality rate is also low among all cancers, the base of patients suffering from this cancer is large!

There are millions of new patients a year, but Ruikang's gene editing drugs have no effect on this cancer. How much money will it cost to lose every year!

Apart from nmsc, the second most common cancer is breast cancer, but the number of new breast cancer cases every year is only about two million, which is incomparable to seven million!

Next, there are more than one million new cases of colorectal cancer, prostate cancer, gastric cancer and other cancers every year, and then there are only a few hundred thousand new cases of liver cancer, cervical cancer and other cancers every year.

This is equivalent to the total of 2-10 cancer cases in the top ten incidence rates each year, which is equivalent to the new cases of nmsc cancer!

However, compared with skin cancers with a lower mortality rate and less malignant degree, other cancers need cancer gene editing drugs more urgently.

For example, the second highest incidence rate of trachea, bronchial and lung cancer, there were 2.2 million new cases last year, and 1.9 million people died of this type of cancer!

Colorectal cancer, the third highest incidence rate, had 1.8 million new cases worldwide last year, and 896,000 people died of colon cancer, with a very high mortality rate!

Fortunately, except for most skin cancers, Ruikang's cancer gene editing drugs can basically work on other cancers.

You only need to add these cancer genes to the CRISPR genome spacer in the drug, that is, blacklist them, and then the Cas9 gene in the drug will be responsible for removing these cancer genes.

These cancers with very high mortality rates are urgently needed for treatment, and Ruikang's cancer gene editing drugs can provide treatment for these cancers and prolong the survival of patients!

When cancer gene editing drugs were officially launched in Denmark and were successively used on more than 20,000 cancer patients in Denmark, it caused a stir throughout Denmark!
Chapter completed!